Patents by Inventor Swarnendu KAVIRAJ

Swarnendu KAVIRAJ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LYOPHILISED FORMULATIONS OF mRNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES
    Publication number: 20240350413
    Abstract: Lyophilised formulations of mRNA adsorbed onto lipid nano-emulsion particles. The present invention relates to lyophilised formulations of mRNA adsorbed onto lipid nano-emulsion particles. It particularly provides a method for lyophilisation of liquid 5 formulations of mRNA adsorbed onto lipid nano-emulsion particles under the conditions that maintain the integrity and pharmaceutical properties of resultant lyophilised formulations for the extended periods at storage temperature of about 5° C.
    Type: Application
    Filed: August 24, 2022
    Publication date: October 24, 2024
    Inventors: Swarnendu KAVIRAJ, Sanjay SINGH, Sunil RAUT, Pavan KARDILE, Ajay SINGH
  • RNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES AND ITS FORMULATIONS
    Publication number: 20240325522
    Abstract: RNA adsorbed onto lipid nano-emulsion particles and its formulations. The present invention relates, a method of preparing a liquid formulation of RNA complexed with lipid nano-emulsion particles or nano-carriers. It particularly provides a method for preparation of the RNA adsorbed onto lipid nano-emulsion particles in liquid and the formulations of said RNA complexes as such.
    Type: Application
    Filed: July 8, 2022
    Publication date: October 3, 2024
    Inventors: Sanjay SINGH, Swarnendu KAVIRAJ, Ajay SINGH, Arjun Singh RAGHUWANSHI, Pavan KARDILE, Shalu SHUKLA, Aishwarya KULKARNI, Praveen AGRA WAL, Sunil RAUT
  • OPTHALMIC COMPOSITION OF BEVACIZUMAB
    Publication number: 20220265825
    Abstract: The present invention pertains to an ophthalmic composition of Bevacizumab, in a single use prefilled syringe which is safe, non-toxic and efficacious for administration during the shelf life, characterised in that the ophthalmic solution is controlled with respect to the number of sub-visible particulate matter with significantly reduced endotoxin levels and with low aggregate level that are suitable for intravitreal use during the shelf life of 2 years of the product.
    Type: Application
    Filed: July 31, 2020
    Publication date: August 25, 2022
    Applicant: GENNOVA BIOPHARMACEUTICALS LIMITED
    Inventors: Kushal GARIMA, Swarnendu KAVIRAJ, Arjun RAGHUWANSHI, Sanjay SINGH